Centrexion Therapeutics Corporation announced completion of patient enrollment in its third Phase 3 trial, VICTORY-3. VICTORY-3 is a randomized, open-label, single injection (per knee), eight-week study of 857 participants designed to streamline and optimize CNTX-4975 administration procedure and patient comfort as well as to evaluate the efficacy and safety of an injection of 1.0 mg of CNTX-4975 in patients with chronic moderate-to-severe knee osteoarthritis (OA) pain in one or both knees. Topline results from VICTORY-3 are expected to be reported in the first quarter of 2020. VICTORY-3 will evaluate the comfort and ease of use of five different cooling treatment regimens: Breg cooling, gel pack cooling, shortened gel pack cooling and single needle injection gel pack cooling with two different strengths of lidocaine (2% and 1%). CNTX-4975 is an investigational synthetic, ultra-pure intra-articular injection of trans-capsaicin that is designed to be injected directly into the site of pain. It harnesses the natural analgesic power of trans-capsaicin to provide durable and targeted pain relief, with onset of response by the second day after injection.